Lipocine up after drug improves fat-free mass in obesity patients in trial

Lipocine

11/04/2024 13:10

** Shares of Lipocine  LPCN.O  up 5.1% to $6.8 premarket 
    ** Co says its experimental drug showed statistically
significant body composition improvement in men with obesity in
a mid-stage trial
    ** The drug candidate, LPCN 2401, increased fat free mass in
patients by 6.7% and decreased fat mass by 6.7% - company
    ** The company tested the drug as an adjunct therapy 
    ** LPCN 2401 when given in combination with or after
treatment with GLP-1 class of drugs may improve muscle mass,
quality, and functionality while maintaining weight loss and
amplifying fat loss, co added  
    ** LPCN 2401 resulted in numerically greater fat mass loss
vs in trial patients who were administered a monotherapy 
    ** The company plans a meeting with the U.S. FDA to discuss
further development of LPCN 2401
    ** As of last close, stock up 133% YTD  

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))